Pyxis Oncology PYXS 深 滬
等待開盤 09-17 09:30:00 美东时间
3.34
+0.010
+0.30%
華盛通- 最 高3.42
- 今 開3.34
- 成交量 63.98万股
- 最 低 3.32
- 昨 收 3.33
- 總市值 27.86万
- 52周最高 5.55
- 市盈率 靜 --
- 換手率 0.77%
- 52周最低 1.03
- 委 比 71.94%
- 總股本 8.34万
- 歷史最高 19.00
- 量 比 0.43
- 振 幅 3.00%
- 歷史最低 0.8332
- 每 手 1
- 風險率 1.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug
Pyxis Oncology Inc. (NASDAQ:PYXS) on Wednesday shared updated data from its Phase 1 trial evaluating micvotabart pelidotin (MICVO). The ongoing global study tested the drug as a monotherapy for patients facing second-line and beyond recurrent or metastatic head and neck squamous cell carcinoma. Prom...
09-10 01:42
Pyxis Oncology Reports Promising MICVO Phase 1 Results
The latest announcement is out from Pyxis Oncology ( ($PYXS) ). On September 9,...
09-09 19:58
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know
Pyxis Oncology Inc (NASDAQ:PYXS) shares gained 5.91% to $4.12 in overnight trading Tuesday, following the company’s leadership announcement and an upcoming clinical data webcast. New CEO Brings Track Record Of Major Deals The Boston-based clinical-stage biopharmaceutical company appointed Thomas Civ...
09-09 16:01
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Pyxis Oncology will host a live webcast on September 9, 2026, at 7:30 a.m. ET to present updated clinical data on micvotabart pelidotin (MICVO) for treating recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The event will feature scientific insights, treatment landscape implications, efficacy and safety results, and future clinical plans. MICVO, an antibody-drug conjugate targeting EDB+FN in the tumor microenvironment, is be...
09-08 20:01
Pyxis Oncology Appoint Thomas Civik Chairman, CEO, Effective Sept. 4
Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that its Board of Directors has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective as of September 4, 2026. Mr. Ci...
09-08 19:32
Pyxis Oncology Files Prospectus For Offering 39.2M Common Shares On Behalf Of Selling Shareholders
https://www.sec.gov/Archives/edgar/data/1782223/000119312526359246/pyxs-20260820.htm
08-21 04:31
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
Pyxis Oncology Q2 EPS $(0.40) Misses $(0.35) Estimate
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 14.29 percent. This is a 33.33 percent decrease over losses of $(0.30) per share from the same period last year.
08-13 19:14
